Pravastatin
- Atc Codes:C10AA03
- CAS Codes:81131-70-6#81093-37-0
- PHARMGKB ID:81131-70-6#81093-37-0
Table of contents
- Brand Names
- Drug Combinations
- Chemistry
- Pharmacologic Category
- Mechanism of Action
- Therapeutic Use
- Pregnancy and Lactation Implications
- Contraindications
- Warnings and Precautions
- Adverse Reactions
- Caution and personalized dose adjustment in patients with the following genotypes
- Other genes that may be involved
- Substrate of
- Inhibits
- Induces
- Drug Interactions
- Nutrition/Nutraceutical Interactions
- Dosage
- Pharmacokinetics and Pharmacodynamics
- Special Considerations
Brand Names
Europe
Austria: Panchol, Pravahex, Pravapharm, Pravasan, Pravastatin, Statinoprav; Belgium: Prareduct, Pravasine, Pravastatine; Bulgaria: Pravastatin; Czech Republic: Vitastat; Denmark: Pravastatin, Pravastatinnatrium; Estonia: Lipostat, Pravahexal, Pravastatin; Finland: Pravachol, Pravastatin; France: Elisor, Pravastatine, Vasten; Germany: Lipifacil, Mevalotin, Prava, Pravabeta, Pravagamma, Pravagodur, PravaLich, Pravalip, Pravapharm, Pravasin, Pravastatin, Satonav, Selipran, Sigaprava, Susalor; Greece: Analpin, Antisterin, Asto-Chol, Cholipravin, Cosivatin, Defantum, Liplow, Lipoprav, Maxudin, Ositron, Panlipol, Pravachol, Pravadium, Pravafact, Pravahelp, Pravalen, Pravalip, Pravalong, Pravanox, Pravastatin, Pravaxis, Pravedol, Pravin, Pravosenil, Privast, Sosmin, Vastil, Venitan, Zoter, Zyon; Ireland: Bellprav, Beneprav, Bystat, Lipaprav, Lipostat, Lipovas-Ranbaxy, Pravalo, Pravamel, Pravastatin, Pravat, Pravitin; Italy: Aplactin, Prasterol, Pravaselect, Sanaprav, Selectin; Luxembourg: Pravasine, Pravastatin; Netherlands: Lipratif, Pravandrea, Pravastatin, Pravastatine, Pravastatinenatrium, Selektine, Statifil, Vastatifix; Poland: Costa, Lipostat, Polstatin, Pralip, Prava, Pravastatine, Pravastin, Pravator; Portugal: Pravacol, Pravastatina, Sanaprav; Romania: Pralip, Pravastatin, Pravator; Slovenia: Pralip, Pravastatin; Spain: Bristacol, Lipemol, Liplat, Minuscol, Prareduct, Pravastatina, Pritadol; Sweden: Pravachol, Pravastatin; UK: Lipostat.
North America
Canada: Pravachol, Pravastatin; USA: Pravachol, Pravastatin.
Latin America
Argentina: Pravacol; Brazil: Mevalotin, Pravacol, Pravastatina; Mexico: Astin, Brakhor, Celuterol, Colpradín, Emival, Kenstatín, Kenvastín, Lexet, Loretsín, Mavitina, Novina, Paver, Piflaxán, Prascolend, Prasiver, Pravacol, Pravastatina, Striacol, Tissulest, Tratinal, Tridanil, Valprastín, Vaprasil, Varlex, Vastorán, Xipral.
Asia
Japan: Alsetin, Cholerit, Liduc, Maibastan, Mevalation, Mevalect, Mevalilin, Mevalocut, Mevalotin, Mevan, Mevarich, Mevasrolin, Mevastan, Mevatorte, Mindorotin, Olipis, Pramevan, Pravalon, Pravamate, Pravastan, Pravatin, Provatin, Tatsuplamin.
Drug combinations
Pravastatin and Aspirin
Chemistry
Pravastatin Sodium: C~23~H~35~NaO~7~. Mw: 446.51. (1) 1-Naphthaleneheptanoic acid, 1,2,6,7,8,8a-hexahydro-β,δ,6-trihydroxy-2-methyl-8-(2-methyl-1-oxobutoxy)-, monosodium salt, [1S-[1α(βS*,δS*),2α,6α,8β(R*),8aα]]-; (2) Sodium (+)-(βR,δR,1S,2S,6S,8S,8aR)-1,2,6,7,8,8a-hexahydro-β,δ,6,8-tetrahydroxy-2-methyl-1-naphthaleneheptanoate, 8-[(2S)-2-methylbutyrate]. CAS-81131-70-6; CAS-81093-37-0 (pravastatin)(1988).
Pharmacologic Category
Antilipemic Agents; HMG-CoA Reductase Inhibitors. (ATC-Code: C10AA03).
Mechanism of action
A competitive inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase.
Therapeutic use
Primary prevention of coronary events (reduction of cardiovascular morbidity (myocardial infarction, coronary revascularization procedures) and mortality). Secondary prevention of cardiovascular events in established coronary heart disease (slowing of progression of coronary atherosclerosis, reduction of cardiovascular morbidity (myocardial infarction, coronary vascular procedures) and reduction of mortality, reduction of risk of stroke and transient ischemic attacks). Hyperlipidemias (reduction of elevations in total cholesterol, LDL-C, apolipoprotein B, and triglycerides). Heterozygous familial hypercholesterolemia.
Pregnancy and lactiation implications
Cholesterol biosynthesis may be important in fetal development. Contraindicated in pregnancy and breast-feeding.
Unlabeled use
Contraindications
Hypersensitivity to pravastatin or any component of the formulation. Active liver disease. Unexplained persistent elevations of serum transaminases. Pregnancy. Breast-feeding.
Warnings and precautions
Patients receiving HMG-CoA reductase inhibitors developed rhabdomyolysis with acute renal failure and/or myopathy (risk increased with concurrent use of other lipid-lowering medications). Use caution in renal impairment, inadequately treated hypothyroidism, and other drugs associated with myopathy (e.g. colchicine). Use with caution in hepatic impairment and/or ethanol use, and in elderly patients (predisposed to myopathy). Treatment not recommended in patients <8 years of age. Secondary causes of hyperlipidemia should be ruled out prior to therapy.